A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

American Heart Journal

Volumn 153, Issue 1, 2007, Pages 66.e9-66.e16

  Brandt, John T ^a   Payne, Christopher D ^a   Wiviott, Stephen D ^b   Weerakkody, Govinda ^a   Farid, Nagy A ^a   Small, David S ^a   Jakubowski, Joseph A ^a   Naganuma, Hideo ^c   Winters, Kenneth J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; DRUG METABOLITE; PRASUGREL;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA;

EID: 33845451677     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.10.010     Document Type: Article

References (38)

1. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the management of patients with unstable angina). J Am Coll Cardiol 36 (2000) 970-1056
2. Schulman S.P. Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes. JAMA 292 (2004) 1875-1882
3. Bertrand M.E., Legrand V., Boland J., et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 98 (1998) 1597-1603
4. Cutlip D.E., Leon M.B., Ho K.K., et al. Acute and nine-month clinical outcomes after "suboptimal" coronary stenting: results from the STent Anti-thrombotic Regimen Study (STARS) registry. J Am Coll Cardiol 34 (1999) 698-706
5. Kastrati A., Mehilli J., Schuhlen H., et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350 (2004) 232-238
6. Mehta S.R., Yusuf S., Peters R.J.G., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358 (2001) 527-533
7. Urban P., Macaya C., Rupprecht H.J., et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 98 (1998) 2126-2132
8. Niitsu Y., Jakubowski J.A., Sugidachi A., et al. Pharmacology of CS-747 (Prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y(12) receptor antagonist activity. Semin Thromb Hemost 31 (2005) 184-194
9. Savi P., and Herbert J.M. Clopidogrel and ticlopidine: P2Y(12) adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 31 (2005) 174-183
10. Coukell A.J., and Markham A. Clopidogrel. Drugs 54 (1997) 745-750
11. Bertrand M.E., Rupprecht H.-J., Urban P., et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102 (2000) 624-629
12. Aleil B., and Gachet C. The inter-individual variability of the response to clopidogrel. Arch Mal Coeur Vaiss 98 (2005) 216-225
13. Gurbel P.A., Bliden K.P., Hiatt B.L., et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
14. Jaremo P., Lindahl T.L., Fransson S.G., et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 252 (2002) 233-238
15. Lau W.C., Gurbel P.A., Watkins P.B., et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109 (2004) 166-171
16. Lepantaloa A., Virtanen K.S., Heikkila J., et al. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J 25 (2004) 476-483
17. Mobley J.E., Bresee S.J., Wortham D.C., et al. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 93 (2004) 456-458
18. Muller I., Besta F., Schulz C., et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89 (2003) 783-787
19. Serebruany V.L., Steinhubl S.R., Berger P.B., et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45 (2005) 246-251
20. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
21. Barragan P., Bouvier J.L., Roquebert P.O., et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59 (2003) 295-302
22. Cuisset T., Frere C., Quilici J., et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4 (2006) 542-549
23. Sugidachi A., Asai F., Ogawa T., et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 129 (2000) 1439-1446
24. Wiviott S.D., Antman E.M., Winters K.J., et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111 (2005) 3366-3373
25. Pang H., Kawabata K., Takahashi M., et al. Stabilization of R-138727, the active metabolite of prasugrel (CS747/LY640315), in whole blood and its assay in human plasma by LC-MS/MS (abstract). J Am Soc Mass Spectrom 16 (2005) 98S Abstract 127
26. Fontana P., Dupont A., Gandrille S., et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108 (2003) 989-995
27. Nguyen T.A., Diodati J.G., and Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45 (2005) 1157-1164
28. Wiviott S.D., Antman E.M., Wiviott S.D., et al. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 109 (2004) 3064-3067
29. Labarthe B., Theroux P., Angioi M., et al. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 46 (2005) 638-645
30. Sugidachi A., Ogawa T., and Asai F. Active metabolites of CS-747 (Prasugrel, LY640315) and clopidogrel show similar in vitro P2Y12 receptor blockade but greater in vivo potency of CS-747 (abstract). J Thromb Haemost 1 (2005) P1109
31. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 25 (2004) 1903-1910
32. Gorchakova O., von Beckerath N., Gawaz M., et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 25 (2004) 1898-1902
33. Hochholzer W., Trenk D., Frundi D., et al. Time dependence of platelet inhibition after a 600 mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 (2005) 2560-2564
34. Kastrati A., von Beckerath N., Joost A., et al. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 110 (2004) 1916-1919
35. Taubert D., Kastrati A., Harlfinger S., et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 92 (2004) 311-316
36. von Beckerath N., Taubert D., Pogatsa-Murray G., et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112 (2005) 2946-2950
37. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY Study. JAMA 294 (2005) 1224-1232
38. Jernberg T., Payne C.D., Winters K.J., et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 27 (2006) 1166-1173